Untargeted Plasma Metabolomics Unveils Distinct Metabolite Profiles in Parkinson Disease Subtypes: A Focus on idiopathic REM Sleep Behavior Disorders
BackgroundParkinsons disease (PD) is characterized by diverse clinical presentations and etiological complexities, with rapid eye movement (REM) sleep behavior disorder (RBD) serving as a prodromal marker. While extensive unbiased metabolic profiling of plasma samples from PD subjects has been conducted to identify novel PD metabolic biomarkers, comprehensive metabolic profiling of PD subtypes based on RBD status remains limited. MethodsWe conducted a comprehensive metabolic profiling of PD subtypes at disease onset, considering the presence or absence of RBD, utilizing an untargeted metabolomics approach. Plasma samples were collected from subjects with PD with and without RBD at the initial stages of disease, idiopathic RBD, and healthy controls to elucidate similarities and differences among PD subtypes. Based on ordination analysis and metabolome-wide association study (Wilcoxon rank-sum tests and generalized fold changes), we identified specific groups of metabolites enriched in the PD_Only group and RBD groups (iRBD & PD_RBD+), with few metabolites shared between groups. Furthermore, pathway enrichment analysis (hypergeometric tests) identified specific groups enriched with metabolites from specific origins and associated biospecimens, as well as disease-associated metabolites. Finally, we evaluated the biomarker potential of the identified disease metabolites by ROC curves and proposed logistic regression models of key biomarkers and clinical parameters for predicting disease status. ResultsMetabolomic analysis revealed distinct metabolic profiles between PD subtypes with and without RBD. Our analysis confirmed previously reported PD metabolic markers, such as a reduction in caffeine and urate, as well as an increase in cortisol, secondary bile acids, and p-cresol sulfate. However, our stratified analyses based on the presence of RBD discriminated RBD-associated metabolites from those associated with PD_Only (without RBD). PD patients with RBD exhibited enrichment of gut microbial-origin metabolites, including secondary bile acids and p-cresol sulfate, compared to PD patients without RBD. Conversely, metabolites associated with neuro-psychiatric diseases were enriched in PD patients without RBD. ConclusionsOur study elucidates the heterogeneous nature of PD subtypes, particularly differentiated with the presence of RBD. The metabolic features of PD with RBD subtype supports the "body-first" concept of PD pathogenesis originating from the gut.